Table 3.
Characteristics, study design and methodological aspects of the main prospective cohort studies which have assessed the risk of future intracerebral hemorrhage in relation to the presence of cerebral microbleeds (CMBs).
| Study | Country | Participants |
Antithrombotic users |
T2*-GRE MRI parameters |
CMBs prevalence | FU time | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Mean age, y | Antiplatelet users | Warfarin users | Field strength (Tesla) | Echo time (ms) | Section thickness (mm) | ||||
| Thijs et al. (2010) | Belgium | 487 | 72 | 32% | 1/1.5/3 | 35/26/16 | 7 | 26.5% | 2.2 years (median) | |
| Orken et al. (2009) | Turkey | 141 | 65.8 | – | 100% | 1.5 | 15 | 5 | 22% | 3.94 years (mean) |
| Soo et al. (2008) | China | 908 | – | 92.5% | 4.3% | 1.5 | 30 | 5 | 27.8% | 26.6 months (mean) |
| Naka et al. (2006) | Japan | 183 | – | – | – | 1 | 26 | 5 | 29% | 1.54 years |
| Boulanger et al. (2006) | Canada | 236 | – | 23.7% | – | 3 | 20 | 5 | 19.1% | 14 month (median) |
| Fan et al. (2003) | China | 121 | 68 | 80% | 5.8% | 1.5 | 30 | 5 | 35.5% | 27.5 months (mean) |